LENERKUSEN, NORTH RHINE-WESTPHALIA, Germany (The Adobo Chronicles) – The U.S. Food and Drug Administration (FDA) has given the green light to Bayer Pharmaceuticals for the marketing of the first drug to cure selfitis, an inflammation of the ego which last year was officially declared a mental disorder by the American Psychiatric Association.

Bayer is a German chemical and pharmaceutical company founded in Barmen, Germany in 1863. It is headquartered in Leverkusen, North Rhine-Westphalia, Germany and well is known for its original brand of aspirin.

The FDA approval came after successful Phase III clinical trials which showed the new pill’s overwhelming safety and efficacy in combatting selfies – the taking of photos of one’s self and posting them on social media.

Because selfitis has become a highly contagious worldwide epidemic, the FDA granted Bayer a fast track approval process. FDA drug approval takes takes anywhere from 10 to 15 years, but it took just 14 months for Bayer to gain the marketing green light.

The new drug comes in pill form and requires a doctor’s prescription. Dosage is different for men and women.  Men need to take one pill a day while women need 5  pills.  Neither Bayer nor the FDA had any explanation on the dosage discrepancy.

Bayer is now pursuing drug approval in Europe and Asia.